LUSPAMARK: Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patients (clinicaltrials.gov) - Sep 21, 2026 - P4 | N=150 | Not yet recruiting | Sponsor: University Hospital, Grenoble
Biomarker • New P4 trial • Hematological Malignancies • Myelodysplastic Syndrome • Oncology
|